Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 12/15/2020 (updated 4/3/2024)
This presentation covered recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of SUD and drug overdose. Also, presenters discussed the impact of the pandemic on corrections and the actions of states in response to COVID as it affects those with SUD. Presenters gave an overview of how recovery housing in this context can be developed especially in rural areas.
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed considerations in engaging and treating individuals with stimulant use disorders and presented evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 12/15/2020 (updated 4/3/2024)
This workshop presented strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session focused on communication skills, assessment techniques, and building motivation to make healthier choices. The presentation looked at programmatic and clinical level integration strategies and offered participants a chance to assess current service delivery models and develop a plan to enhance care.
Posted 12/15/2020 (updated 4/3/2024)
Participants learned evidenced based harm reduction strategies to keep people who use drugs (PWUD) alive with reduced disease burden. Presenters discussed methods of engaging PWUD, linkages to MOUD, behavioral health and recovery supports for individuals ready for these supports
Posted 12/15/2020 (updated 4/3/2024)
The presenters reviewed the structure and function of state substance use prevention systems, described the role and activities of the national prevention network, and highlighted rural prevention initiatives.
Posted 6/12/2020 (updated 3/28/2024)
The HHS Office of the Assistant Secretary for Health (OASH) Regional Health Administrators presented a webinar series highlighting resources, policies, and assistance for developing and expanding SSPs in diverse settings and in different communities across the country, the three webinars were held in 2019.
Posted 5/11/2020 (updated 3/28/2024)
The United States is in the midst of an epidemic of prescription opioid overdoses. The amount of opioids prescribed and sold in the US quadrupled since 1999, but the overall amount of pain reported by Americans hasn’t changed. This epidemic is devastating American lives, families, and communities.
Posted 8/24/2020 (updated 3/28/2024)
Syringe service programs (SSPs), which provide access to sterile syringes and other injection equipment and their safe disposal after use,* represent a highly successful human immunodeficiency virus (HIV) prevention intervention. SSPs are associated with a 58% reduction in the incidence of HIV infection among persons who inject drugs. In addition, SSPs have led efforts to prevent opioid overdose deaths by integrating evidence-based opioid overdose education and naloxone distribution (OEND) programs. OEND programs train laypersons to respond during overdose events and provide access to naloxone and directions for drug delivery. SSPs are ideal places for OEND because they provide culturally relevant services designed to reach persons at high risk for experiencing or observing an opioid overdose.
Posted 12/13/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) announced the progress made since the release of the Overdose Prevention Strategy (Strategy) last fall. The new data shows treatment capacity, lives saved from overdose, and commitments to long-term recovery supports, as well as a hopeful trend of a decrease in overdose deaths.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.